VIROLOGIK GMBH
ViroLogik is a biopharmaceutical company which is focusing on innovative drugs for treatment of viral diseases. The focus is on Hepatitis C (HCV). Second indication is HIV- (Human Immunodeficiency Virus, AIDS) infections. ViroLogik is following a novel strategy to prevent formation of drug resistance. ViroLogik has clinical proof of concept with a proteasome inhibitor in Hepatitis C patients refractory to standard therapy. Formal preclinical development of ViroLogik’s own development candi... date VL-01 is progressing. ViroLogik is following a novel strategy to prevent formation of drug resistance. The approach aims at inhibition of the highly conserved host cell proteasome which is essential for viral replication. This is in contrast to many current drugs which target fast mutating viral proteins and, hence, are prone to induction of drug resistance.
VIROLOGIK GMBH
Social Links:
Industry:
Clinical Trials Manufacturing Medical
Founded:
2006-01-01
Address:
Jena, Thuringen, Germany
Country:
Germany
Website Url:
http://www.virologik.com
Total Employee:
1+
Status:
Closed
Contact:
(364) 163-6442
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Font Awesome Nginx Amazon IPv6
Current Advisors List
